You might say that Express Scripts has a bad case of the blues lately. Its stock plummeted in the weeks following a public statement by Anthem, the largest Blue Cross and Blue Shield plan, that it ...

ST. LOUIS -- Shares of Express Scripts Inc., among the nation's largest pharmacy benefit managers, extended their 52-week high on Friday, courtesy of its expectations of a better-than-expected first ...

Citron Research’s tweet suggesting President-elect Donald Trump begin his war on drug pricing with pharmacy benefit manager Express Scripts caused the company’s stock to fall as much as 9 percent ...

They're the two biggest pharmacy benefits managers in the world, and they compete against each other every day. While CVS Health boasts a higher market cap thanks to its retail pharmacies, Express ...

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmacy benefit manager Express Scripts has earned a respected ...

Carl Icahn doesn't want the health insurer Cigna's $67 billion deal with Express Scripts. Icahn, who recently took a stake in Cigna, wrote in a letter to Cigna shareholders Tuesday that the deal "may ...

NASHVILLE, Tenn. (AP) - Pharmacy benefits manager Express Scripts is commencing an exchange offer for outstanding shares of its rival Caremark Rx Incorporated, which has rejected Express Scripts' ...

Last year was blah for Express Scripts Holding Company shareholders. The giant pharmacy benefit manager's stock turned in 3% gain -- well below the 21% jump from the previous year. After just a few ...

NEW YORK (Reuters) - Express Scripts Inc. on Tuesday launched a $24.8 billion offer for Caremark Rx Inc. , the latest step in a high-stakes takeover battle after Caremark last week said it preferred a ...

The Cigna Group’s CI pharmacy benefits manager, Express Scripts, recently partnered with CPESN USA to enhance access to comprehensive care at independent pharmacies. CPESN USA is a network of pharmacy ...

June 19 (Reuters) - UBS downgraded two major U.S. pharmacy benefit managers, saying potential benefits from the launch of a generic version of Pfizer Inc's blockbuster cholesterol drug Lipitor were ...